- Home
- EXOZ vs MDXH Comparison
EXOZ vs MDXH Comparison
Compare EXOZ & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXOZ
- MDXH
- Stock Information
- Founded
- EXOZ 2014
- MDXH 2003
- Country
- EXOZ United States
- MDXH Belgium
- Employees
- EXOZ N/A
- MDXH N/A
- Industry
- EXOZ
- MDXH
- Sector
- EXOZ
- MDXH
- Exchange
- EXOZ NYSE
- MDXH Nasdaq
- Market Cap
- EXOZ 89.8M
- MDXH 84.6M
- IPO Year
- EXOZ N/A
- MDXH 2021
- Fundamental
- Price
- EXOZ $9.98
- MDXH $2.49
- Analyst Decision
- EXOZ
- MDXH Buy
- Analyst Count
- EXOZ 0
- MDXH 1
- Target Price
- EXOZ N/A
- MDXH $6.00
- AVG Volume (30 Days)
- EXOZ 7.9K
- MDXH 62.0K
- Earning Date
- EXOZ 08-15-2025
- MDXH 08-20-2025
- Dividend Yield
- EXOZ N/A
- MDXH N/A
- EPS Growth
- EXOZ N/A
- MDXH N/A
- EPS
- EXOZ N/A
- MDXH N/A
- Revenue
- EXOZ N/A
- MDXH $94,507,000.00
- Revenue This Year
- EXOZ N/A
- MDXH $23.51
- Revenue Next Year
- EXOZ N/A
- MDXH $17.68
- P/E Ratio
- EXOZ N/A
- MDXH N/A
- Revenue Growth
- EXOZ N/A
- MDXH 25.46
- 52 Week Low
- EXOZ $8.50
- MDXH $1.35
- 52 Week High
- EXOZ $23.99
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- EXOZ N/A
- MDXH 64.84
- Support Level
- EXOZ N/A
- MDXH $2.43
- Resistance Level
- EXOZ N/A
- MDXH $2.75
- Average True Range (ATR)
- EXOZ 0.00
- MDXH 0.09
- MACD
- EXOZ 0.00
- MDXH 0.02
- Stochastic Oscillator
- EXOZ 0.00
- MDXH 57.38
About EXOZ EXOZYMES INC
EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.